Vonoprazan: Clinical Indications, Dosing, and Monitoring
Primary Indications
Vonoprazan should be used as first-line therapy for H. pylori eradication in most patients, but reserved as second-line therapy for most other acid-related disorders due to cost and limited long-term safety data. 1
FDA-Approved Indications 2:
- Erosive esophagitis (EE): Healing of all grades and maintenance of healing
- Non-erosive GERD: Relief of heartburn
- H. pylori infection: In combination with antibiotics
Dosing Regimens
Erosive Esophagitis 2
Healing Phase:
- Standard dose: 20 mg once daily for 8 weeks
- More effective than lansoprazole 30 mg, particularly for severe (LA grade C/D) disease 3
Maintenance Phase:
- Standard dose: 10 mg once daily for up to 6 months
- Vonoprazan 10-20 mg superior to lansoprazole 15 mg for maintaining healing of LA grade C/D EE (75-77% vs 62%) 1
Non-Erosive GERD 2
- 10 mg once daily for 4 weeks
H. pylori Eradication 2
Triple Therapy (14 days):
- Vonoprazan 20 mg twice daily + amoxicillin 1 g twice daily + clarithromycin 500 mg twice daily
- Superior eradication rates vs PPI-based regimens (92% vs 80%), especially in clarithromycin-resistant strains (66-70% vs 32%) 1, 4
Dual Therapy (14 days):
- Vonoprazan 20 mg twice daily + amoxicillin 1 g three times daily
- Effective alternative with 77% eradication rate 4
Dose Adjustments
Renal Impairment 2
Healing of EE:
- eGFR ≥30 mL/min: 20 mg once daily
- eGFR <30 mL/min: 10 mg once daily
H. pylori Treatment:
- eGFR ≥30 mL/min: 20 mg twice daily
- eGFR <30 mL/min: Use not recommended
Maintenance/Non-erosive GERD: No adjustment needed
Hepatic Impairment 2
Healing of EE:
- Child-Pugh A: 20 mg once daily
- Child-Pugh B or C: 10 mg once daily
H. pylori Treatment:
- Child-Pugh A: 20 mg twice daily
- Child-Pugh B or C: Use not recommended
Maintenance/Non-erosive GERD: No adjustment needed
Administration 2
- Take with or without food (major advantage over PPIs)
- Swallow whole; do not crush or chew
- Missed doses:
- GERD indications: Take within 12 hours; otherwise skip
- H. pylori: Take within 4 hours; otherwise skip and continue schedule
Contraindications 2
- Known hypersensitivity to vonoprazan (anaphylactic shock reported)
- Rilpivirine-containing products (significant drug interaction)
- Refer to clarithromycin and amoxicillin prescribing information when using combination therapy
Clinical Positioning by Indication
When to Use Vonoprazan as First-Line 1:
H. pylori eradication (STRONGEST indication):
- Superior to PPIs with 92% vs 80% eradication rates 1
- Particularly effective in clarithromycin-resistant infections
- Short treatment duration (14 days) mitigates cost concerns
When to Consider Vonoprazan as Second-Line 1:
Severe erosive esophagitis (LA grade C/D):
- May use as therapeutic option for healing and maintenance 1
- Superior to lansoprazole for maintenance (75-77% vs 62%) 1
- However, markedly higher cost and lack of comparison with double-dose PPIs limit routine first-line use 1
PPI treatment failures:
- Use in confirmed acid-related reflux (LA grade B or greater EE, Barrett's esophagus, peptic stricture, or acid exposure time >6% on pH monitoring) that fails twice-daily PPI therapy 1
When NOT to Use as First-Line 1:
Mild erosive esophagitis (LA grade A/B):
- Similar efficacy to PPIs (94% vs 91% healing) 1
- Cost not justified given equivalent outcomes
Non-erosive GERD:
- Insufficient evidence of superiority over PPIs 1
Peptic ulcer disease:
- Noninferior but not superior to PPIs 1
- Higher cost not justified for first-line use
Warnings and Monitoring 2
Key Safety Concerns:
Gastric malignancy:
- Symptomatic response does not exclude malignancy
- Consider endoscopy in older patients or those with suboptimal response
Acute tubulointerstitial nephritis:
- Discontinue if suspected and evaluate
Clostridioides difficile-associated diarrhea:
- Use shortest duration appropriate
- Consider CDAD in patients with persistent diarrhea
Bone fracture risk:
- Associated with long-term use
- Manage at-risk patients per osteoporosis guidelines
Severe cutaneous adverse reactions:
- Stevens-Johnson syndrome and toxic epidermal necrolysis reported
- Discontinue at first signs
Vitamin B12 deficiency:
- Long-term acid suppression can cause malabsorption
- Consider workup if clinical symptoms present
Hypomagnesemia:
- May lead to hypocalcemia/hypokalemia
- Monitor in at-risk patients or with concomitant digoxin use
Chromogranin A elevation:
- Stop vonoprazan ≥4 weeks before assessing CgA levels for neuroendocrine tumor workup
Fundic gland polyps:
- Risk increases with long-term use
- Use shortest duration appropriate
Monitoring Recommendations:
- No routine laboratory monitoring required for short-term use
- For long-term use (>6 months):
- Consider magnesium and calcium levels in at-risk patients
- Monitor for vitamin B12 deficiency symptoms
- Assess bone health in patients with osteoporosis risk factors
Common Adverse Events 2
Healing of EE (≥2%): Gastritis, diarrhea, abdominal distension, abdominal pain, nausea
Maintenance of EE (≥3%): Gastritis, abdominal pain, dyspepsia, hypertension, urinary tract infection
Non-erosive GERD (≥2%): Abdominal pain, constipation, diarrhea, nausea, urinary tract infection
H. pylori treatment (≥2%): Diarrhea, dysgeusia, vulvovaginal candidiasis, abdominal pain, headache, hypertension, nasopharyngitis
Key Pharmacologic Advantages Over PPIs 1, 5, 6:
- Rapid onset: Achieves pH >4 within 4 hours (vs 3-5 days for PPIs)
- No meal timing required: Acid-stable, not a prodrug
- Longer half-life: 6-9 hours (vs 1-2 hours for PPIs)
- More consistent response: Not affected by CYP2C19 polymorphisms
- Superior acid suppression: 88% of 24-hour period with pH >4 on day 7 (vs 42% with lansoprazole) 6
Cost-Effectiveness Considerations 1:
Critical limitation: Even modest clinical superiority may not justify cost-effectiveness as first-line therapy given markedly higher US prices compared to standard-dose and double-dose PPIs 1
Exception: H. pylori eradication where short treatment duration and superior efficacy (especially in resistant strains) justify use 1